Annals of the American Thoracic Society is a premier journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by the American Thoracic Society, this journal offers an invaluable platform for researchers and clinicians to disseminate cutting-edge research, clinical insights, and innovative methodologies. With an impressive impact factor and ranked in the top Q1 category of its field (2023) and within the top 20 of 155 according to Scopus rankings, it is positioned as a leading force in shaping clinical practice and research directions. The journal's convergence years from 2013 to 2024 indicate a commitment to providing timely and relevant content at the forefront of pulmonary health. While not an open-access journal, it ensures broad accessibility to its significant contributions in respiratory medicine, making it an essential resource for professionals, researchers, and students alike endeavoring to deepen their understanding and improve outcomes in thoracic health.

RESPIROLOGY is a prestigious academic journal that focuses on the field of Pulmonary and Respiratory Medicine, publishing high-quality research and comprehensive reviews that contribute significantly to the understanding and management of respiratory health. As a distinguished publication of WILEY, it has established a strong presence in the academic world with an impressive impact factor and ranked in the Q1 category, recognized for its influence and innovation in the field. RESPIROLOGY is committed to disseminating cutting-edge research from 1996 through 2024, appearing regularly in SCOPUS with a rank of #14 out of 155, placing it in the rarefied 91st percentile among its peers. The journal invites contributions from researchers, professionals, and students, fostering a collaborative space for advancing knowledge in pulmonary medicine. Although it does not offer open access, its readership spans globally, indicating the high regard in which it is held within the scientific community.

Thoracic Research and Practice is an emerging open access journal published by AVES that aims to advance knowledge in the field of pulmonary and respiratory medicine. Launched in 2022, this journal aspires to provide a platform for innovative research, clinical practices, and advancements in thoracic health. With an E-ISSN of 2979-9139, it caters to a global audience while based in Turkey. Although it currently holds a Q4 category in the 2023 ranking within its field, the journal is dedicated to improving its standing through the inclusion of high-quality, original articles, systematic reviews, and case studies. As it converges years from 2023 to 2024, Thoracic Research and Practice invites researchers, professionals, and students to contribute valuable insights that aim to enhance patient outcomes and propel further exploration in this critical area of medicine.

The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

EXPERIMENTAL LUNG RESEARCH, published by Taylor & Francis Inc, is a pivotal journal within the field of pulmonary and respiratory medicine, with its extensive coverage spanning from 1980 to 2024. The journal is indexed with ISSN 0190-2148 and E-ISSN 1521-0499, marking its commitment to disseminating high-quality research. With its Category Quartile rankings falling within Q3 in Clinical Biochemistry, Molecular Biology, and Pulmonary and Respiratory Medicine as of 2023, EXPERIMENTAL LUNG RESEARCH serves as a crucial platform for researchers and professionals seeking to explore innovative findings and advancements in lung physiology, pathology, and therapeutic approaches. Although currently not Open Access, it offers substantial insights through rigorous peer-reviewed articles that contribute significantly to the scientific community's understanding of respiratory health. With Scopus rankings reflecting its relevance within its categories, this journal attracts a diverse readership interested in advancing the field of lung research.

Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine, published by SAGE Publications Ltd, stands as a vital resource in the fields of Cardiology and Pulmonary Medicine, underscored by its Q3 quartile rankings in both areas for 2023. Established in 2007 as an open-access journal, it facilitates the dissemination of cutting-edge research and observations from the international scientific community. With an ISSN of 1179-5484, the journal has garnered recognition for its contributions to clinical medicine, particularly covering topics of circulatory, respiratory, and pulmonary health. The journal not only aims to bridge the gap between research and clinical practice but also to serve as a platform for innovative ideas and collaborations among researchers, healthcare professionals, and trainees. By offering unrestricted access to its articles, Clinical Medicine Insights ensures that vital knowledge reaches a broad audience, ultimately fostering advancements in medical science and patient care.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, published by the American Physiological Society, stands as a prominent peer-reviewed journal dedicated to advancing the field of lung cellular and molecular physiology. With an impressive impact factor, the journal serves as a crucial platform for disseminating high-quality research focused on the intricate mechanisms underlying pulmonary function and disease. Established in 1989, this journal has consistently ranked within the top quartiles across various categories, including Q1 in Physiology and Pulmonary and Respiratory Medicine, highlighting its significance in the scientific community. The journal covers a wide scope of topics pertinent to cell biology and physiology, catering to the needs of researchers, professionals, and students seeking to explore and contribute to this vital area of study. Although currently not offering open access, it provides comprehensive access options for subscribers, ensuring that vital research is communicated effectively to the global scientific community. With a commitment to fostering innovation and inspiring future studies, the AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY remains an essential resource for those engaged in lung research.

HEART & LUNG is a premier academic journal published by MOSBY-ELSEVIER, focusing on the critical intersections of cardiology, critical care, and respiratory medicine. Since its inception in 1973, the journal has established a significant reputation within the medical community, as evidenced by its impressive Q2 ranking in key categories such as Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, and Pulmonary and Respiratory Medicine for the year 2023. With a dedicated readership comprising researchers, healthcare professionals, and students, HEART & LUNG serves as a vital platform for disseminating cutting-edge research, clinical innovations, and comprehensive reviews that influence practice standards and enhance patient care. While it currently does not offer Open Access options, readers can access a wealth of information pivotal to the advancement of medical knowledge and practice through conventional subscription. Explore the latest findings and contribute to the ever-evolving landscape of cardiovascular and respiratory health through this esteemed journal.

Respiratory Medicine and Research, published by Elsevier, is a pivotal journal in the field of Pulmonary and Respiratory Medicine, dedicated to advancing the understanding and treatment of respiratory diseases. Since its inception in 2019, the journal has provided a platform for high-quality research, contributing significantly to the scientific community's knowledge base, as reflected in its impressive Q2 categorization in 2023. With a Scopus rank of #94 out of 155, placing it in the 39th percentile, this journal is essential for researchers, professionals, and students seeking the latest advancements in respiratory medicine. Although currently categorized as a non-open access publication, it remains accessible to those affiliated with institutions with subscriptions. Published in France, the journal aims to foster collaboration and innovation by highlighting original research, clinical studies, and comprehensive reviews that address pressing issues in respiratory health.

Chronic Respiratory Disease is a leading peer-reviewed journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by SAGE Publications Ltd since its inception in 2004, this open-access journal has been at the forefront of disseminating high-quality research aimed at addressing chronic respiratory conditions. With an impressive impact factor and classified as Q1 in the 2023 category of Pulmonary and Respiratory Medicine, it ranks an admirable #45 out of 155 in Scopus, placing it in the 71st percentile of its field. This journal features a diverse range of studies, reviews, and clinical insights that cater to researchers, healthcare professionals, and students alike, encouraging the exchange of innovative ideas and practices in respiratory disease management. Operating out of London, UK, Chronic Respiratory Disease exemplifies a commitment to openness, having transitioned to open access since 2017, thereby ensuring that pivotal research is readily accessible to a global audience engaged in the improvement of respiratory health.